Claims for Patent: 5,646,015

Summary for Patent: 5,646,015

Title:	Excretion of heterologous proteins from E. coli
Abstract:	A recombinant DNA construct, useful for obtaining excretion from E. coli of a heterologous protein, comprises a coding region in which DNA coding for the heterologous protein in coupled in reading frame with DNA coding for the OmpA signal peptide, to enable secretion of the protein into the periplasm; and a control region linked operably with the coding region to enable expression thereof in an E. coli host, wherein the control region comprises the tac promoter, the lac operator and a consensus ribosome binding site. With this construct, the excretion of heterologous proteins from E. coli can be achieved, consistently and for a wide variety of such proteins, without assistance from carrier proteins or membrane-lytic agent and by using \"healthy\" hosts rather than mutant strains having defective outer membranes.
Inventor(s):	Wong; W. K. Raymond (Mississauga, CA), Sutherland; Margaret L. (Cambridge, GB)
Assignee:	Astra AB (Sodertalje, SE)
Application Number:	08/439,132
Patent Claims:	1. A method for the production of a parathyroid hormone, comprising the steps of (a) obtaining a healthy E. coli bacterium with an excretion vector comprising (i) a coding region comprised of a first DNA that encodes the ompA signal peptide and a second DNA that encodes said parathyroid hormone, wherein said first DNA is linked in-frame to said second DNA; (ii) a control region comprised of a third DNA, said control region operably-linked to said coding region to enable expression of said parathyroid hormone, wherein said third DNA comprises the tac promoter, the lac operator, and a ribosome binding site, and (iii) a selection region comprised of a fourth DNA that encodes a second protein which, upon expression, imparts a selectable phenotype to said bacterium; (b) culturing said transformed E. coli bacterium in a suitable medium; and (c) recovering said parathyroid hormone from said medium without lysing said bacterium. 2. A method according to claim 1, wherein said heterologous protein is human PTH. 3. A method according to claim 1, wherein said vector further comprises a lacI.sup.q DNA derived from Escherichia coli. 4. A method according to claim 1, wherein said vector further comprises a par element DNA derived from Escherichia coli. 5. A method according to claim 1, wherein said vector further comprises a lacI.sup.q DNA and a par element DNA, both derived from Escherichia coli. 6. A method according to claim 5, wherein said vector further comprises a termination signal selected from the group consisting of the trpA, thr, his or phe terminators derived from Escherichia coli. 7. A method according to claim 5, wherein IPTG is added during said culturing. 8. A method according to claim 1, wherein said vector further comprises a termination signal selected from the group consisting of the trpA, thr, his or phe terminators derived from Escherichia coli. 9. A method according to claim 1, wherein said culturing takes place at 30.degree. C. 10. A method according to claim 1, wherein said bacterium is Escherichia coli JM101. 11. A method according to claim 10, wherein said heterologous protein is human PTH. 12. A method according to claim 10, wherein said vector further comprises a lacI.sup.q DNA derived from Escherichia coli. 13. A method according to claim 10, wherein said vector further comprises a par element DNA derived from Escherichia coli. 14. A method according to claim 10, wherein said vector further comprises a lacI.sup.q DNA and a par element DNA, both derived from Escherichia coli. 15. A method according to claim 14, wherein said vector further comprises a termination signal selected from the group consisting of the trpA, thr, his or phe terminators derived from Escherichia coli. 16. A method according to claim 14, wherein IPTG is added during said culturing. 17. A method according to claim 10, wherein said vector further comprises a termination signal selected from the group consisting of the trpA, thr, his or phe terminators derived from Escherichia coli. 18. A method according to claim 10, wherein said culturing takes place at 30.degree. C. 19. A method for obtaining a parathyroid hormone, comprising the steps of: (1) culturing, in a nutrient medium, an E. coli transformant obtained by transforming a healthy E. coli host strain with a secretion vector for directing secretion of said parathyroid hormone to the periplasm of said transformant; and (2) without lysing said transformant, recovering the parathyroid hormone from the medium in which said transformant has been cultured. 20. The method of claim 19, wherein the parathyroid hormone is human parathyroid hormone.

Details for Patent 5,646,015

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-07-08